Article
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced further positive results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant and clinically meaningful improvement in…
Read More
– Freenome examines thirty years of studies to understand differences in predictors of adherence across care settings– Recent studies highlight increased awareness of patient environment and clinical site factors as key predictors of adherence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 15, 2022 /PRNewswire/ — Freenome, a privately held biotech company, presented research at the American Society…
Read More
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Expression Excerpt from the Press Release: SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Iovance…
Read More
Clinical Guidelines Support Adoption of Urinary Biomarker Tests with High Sensitivity and Negative Predictive Values for High-Grade Disease to Replace and/or Postpone Cystoscopies in Low- and Intermediate-Risk NMIBC Publication of Meta-Analysis in European Urology Oncology Showed Bladder EpiCheck has Best Performance Amongst Guideline-Recommended Urinary Biomarker Tests Excerpt from the Press Release: SAN DIEGO & REHOVOT,…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene Corporation and Thomas Jefferson University announced the online publication of the manuscript, “Tadalafil enhances immune response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma”in the American Association for Cancer Research journal Clinical Cancer Research.The study revealed pretreatment head and neck squamous cell carcinoma specimens contain…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule. The…
Read More
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). The final analysis…
Read More
Observed preclinical complete suppression (~95-100%) of tumor SDMA in multiple MTAP-deleted patient derived xenograft (PDX) models across indications Interim IDE397 clinical data demonstrates robust plasma pharmacodynamic modulation, exceeding target of >60% reduction of plasma SAM across all evaluated cohorts Observed clinical exposure-dependent reduction of tumor pharmacodynamic biomarker SDMA in target tumor types, including 95% reduction…
Read More
-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients- -Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial- Excerpt from the Press Release: SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…
Read More
Company expects to report interim safety and biomarker data for Cohort 1 patients in the global phase 1/ 2 clinical trial, GALax-C, by end of 2022 Excerpt from the Press Release: PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Read More